- Home
- AGIO vs BLX Comparison
AGIO vs BLX Comparison
Compare AGIO & BLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BLX
- Stock Information
- Founded
- AGIO 2007
- BLX 1977
- Country
- AGIO United States
- BLX Panama
- Employees
- AGIO N/A
- BLX N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BLX Commercial Banks
- Sector
- AGIO Health Care
- BLX Finance
- Exchange
- AGIO Nasdaq
- BLX Nasdaq
- Market Cap
- AGIO 1.4B
- BLX 1.6B
- IPO Year
- AGIO 2013
- BLX N/A
- Fundamental
- Price
- AGIO $38.80
- BLX $45.95
- Analyst Decision
- AGIO Buy
- BLX
- Analyst Count
- AGIO 6
- BLX 0
- Target Price
- AGIO $57.40
- BLX N/A
- AVG Volume (30 Days)
- AGIO 976.6K
- BLX 130.3K
- Earning Date
- AGIO 07-31-2025
- BLX 08-04-2025
- Dividend Yield
- AGIO N/A
- BLX 5.44%
- EPS Growth
- AGIO N/A
- BLX 12.91
- EPS
- AGIO 11.13
- BLX 5.97
- Revenue
- AGIO $40,875,000.00
- BLX $306,166,000.00
- Revenue This Year
- AGIO $18.94
- BLX $13.23
- Revenue Next Year
- AGIO $201.70
- BLX $7.79
- P/E Ratio
- AGIO $3.49
- BLX $7.70
- Revenue Growth
- AGIO 30.57
- BLX 12.96
- 52 Week Low
- AGIO $23.42
- BLX $29.55
- 52 Week High
- AGIO $62.58
- BLX $47.43
- Technical
- Relative Strength Index (RSI)
- AGIO 58.69
- BLX 64.41
- Support Level
- AGIO $34.71
- BLX $44.48
- Resistance Level
- AGIO $37.73
- BLX $45.26
- Average True Range (ATR)
- AGIO 1.50
- BLX 1.12
- MACD
- AGIO 0.15
- BLX 0.19
- Stochastic Oscillator
- AGIO 82.21
- BLX 78.20
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.